MHC II expression in the CNS after long-term demyelination.
The ability of chronically demyelinated central nervous system (CNS) tissue to express major histocompatibility complex (MHC) class II molecules has been measured in mouse spinal cord cultures exposed for 1 and 3 weeks to demyelinating anti-white matter (WM) serum. From previous studies, it was known that after 3 weeks of demyelination in vitro, such cultures are incapable of remyelination. In the present report, MHC II levels were evaluated by immunocytochemistry and by Western and Northern blots. The results have shown that after both 1 and 3 weeks of exposure to myelinotoxic anti-WM serum, the cultures retained the ability to express MHC II and this could be further upregulated by incubation with interferon gamma (IFN gamma). Control groups showed increased expression of MHC II with age. By immunocytochemistry, all groups of cultures expressed high levels of MHC II and all groups showed upregulation after IFN gamma treatment. Anti-WM-treated cultures demonstrated slightly higher levels of MHC II than controls. Morphologically, the MHC II expression was associated with the surface of astrocytes. Semiquantitative analysis by Western blotting confirmed the increase in class II MHC expression in the long-term treated cultures after IFN gamma exposure, revealing no differences between anti-WM-treated and complement-treated cultures. This was also supported by Northern blotting which showed similar mRNA levels in both groups. These findings suggest that long-term demyelinated CNS tissue still possesses the ability to interact with CD4+ T cells, observations of significance to the expansion of the chronic multiple sclerosis lesion.
Cannella
B
B
Department of Pathology (Neuropathology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Aquino
D A
DA
Raine
C S
CS
D000818:Animals; D015153:Blotting, Western; D003711:Demyelinating Diseases; D005786:Gene Expression Regulation / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis* / Q000235:genetics; D007106:Immune Sera / Q000633:toxicity; D007371:Interferon-gamma / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D009924:Organ Culture Techniques; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D012337:RNA, Ribosomal, 18S / Q000096:biosynthesis / Q000235:genetics; D011817:Rabbits; D011994:Recombinant Proteins; D013116:Spinal Cord / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism
D000949:Histocompatibility Antigens Class II; D007106:Immune Sera; D012333:RNA, Messenger; D012337:RNA, Ribosomal, 18S; D011994:Recombinant Proteins; D007371:Interferon-gamma